Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the APP/PS1 Alzheimer’s disease mouse model by regulating the expression of APP secretases

Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the APP/PS1 Alzheimer’s disease mouse model by regulating the expression of APP secretases

Abstract Background Alzheimer’s disease (AD) is a degenerative neurological disorder. Recent studies have indicated that histone deacetylases (HDACs) are among the most prominent epigenetic therapy targets and that HDAC inhibitors have therapeutic effects on AD. Here, we identified sodium valproate...

Full description

Bibliographic Details
Main Authors: Miaomiao Zhang, Wanyao Wang, Qun Ye, Yun Fu, Xuemin Li, Ke Yang, Fan Gao, An Zhou, Yonghui Wei, Shuang Tian, Shen Li, Fengjiang Wei, Wentao Shi, Wei-Dong Li
Format: Article
Language:English
Published: BMC 2024-01-01
Series:Alzheimer’s Research & Therapy
Subjects:
VPA
WT161
Alzheimer’s disease
Histone deacetylase
Aβ deposition
Cognitive function
Online Access:https://doi.org/10.1186/s13195-024-01384-0

Internet

https://doi.org/10.1186/s13195-024-01384-0

Similar Items